Abstract 1574: Lymphocyte GRK2 as a Novel Biological Marker of Alzheimer’s Disease
In Alzheimer’s disease (AD), alterations in β-adrenergic receptor (β-AR) signalling have been found in both post-mortem cerebrocortical and peripheral lymphocytes. Decreased β-ARs number, altered β-ARs affinity, or a defective G-protein-enzyme coupling could account for β-AR dysfunction . GRK2 is an important modulator of β-AR signalling, involved in receptorial phosforylation and desensitization. The aim of this study was to evaluate GRK2 expression in lymphocytes of AD pts and to establish a relationship between protein levels and severity of the disease. The study included 34 pts with possible or probable AD (NINCDS/ADRDA criteria), clinically stratified into mild or moderate/severe. Cognitive decline was assessed by Mini Mental State Examination (MMSE), Geriatric Depression Scale (GDS), Basic Activity of Daily Life (BADL), Instrumental Activity of Daily Life (IADL). Cardiovascular comorbidity was also assessed due to recent evidences indicating GRK2 upregulation in lymphocytes of pts with hypertension and heart failure. Table⇓ illustrates demographic and clinical characteristics of AD pts. Figure⇓ illustrates GRK2 western blotting assay on human lymphocytes from AD pts. Our data indicate that lymphocyte GRK2 levels seem to correlate with the severity of the disease. Further studies are needed to establish the potential role of this kinase as biological marker of AD.